Individual differences in the concentration of remazolam-induced loss of consciousness and related EEG studies

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200055226

Enrollment

Unknown

Registered

2022-01-03

Start date

2022-01-03

Completion date

Unknown

Last updated

2023-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group M:Remazolam

Group F:Remazolam

Eligibility

Sex/Gender

All

Age

18 Years to 89 Years

Inclusion criteria

Inclusion criteria: 1. Patients with elective general anesthesia, aged 18-89 years, BMI 20-30; 2. ASA classification I-II; 3. No history of smoking and long-term coffee drinking, no alcohol consumption or insomnia 3 days before surgery; 4. All female patients had regular menstrual cycles and did not take contraceptives.

Exclusion criteria

Exclusion criteria: 1. History of schizophrenia, mania, neurological disease; 2. Medication history of psychotropic drugs; 3. History of other serious systemic diseases.

Design outcomes

Primary

Measure	Time frame
Anesthetic consumption;Prefrontal EEG features;	—

Countries

China

Contacts

Public ContactLiu Xuesheng

The First Affiliated Hospital of Anhui Medical University

liuxuesheng@ahmu.edu.cn+86 18655193385

Outcome results